<DOC>
	<DOCNO>NCT00685945</DOCNO>
	<brief_summary>The purpose study determine give isosorbide , drug use treat chest pain , affect blood vessel release anti-clotting factor .</brief_summary>
	<brief_title>Renin-Angiotensin Aldosterone System Fibrinolysis Interaction Humans-Specific Aim 3</brief_title>
	<detailed_description>To test hypothesis administration NO donor isosorbide dinitrate , phosphodiesterase inhibitor sildenafil , attenuate stimulate vascular t-PA release whereas agent improve glucose uptake .</detailed_description>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<mesh_term>Kininogens</mesh_term>
	<mesh_term>omega-N-Methylarginine</mesh_term>
	<criteria>1870 year age Male female subject Surgical sterilization Childbearing potential : beta HCG study day Subjects body mass index 25 great Diabetes type 1 type 2 define fast glucose 126 mg/dl great use antidiabetic medication Use hormone replacement therapy Statin therapy In hypertensive subject , seat systolic blood pressure great 179 mmHg seat diastolic blood pressure great 110 mmHg take hypertensive Pregnancy/Breast Feeding Cardiovascular disease myocardial infarction 6 month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy acceptable ) deep vein thrombosis , pulmonary embolism , second three degree heart block , mitral valve stenosis , aortic stenosis , hypertrophic cardiomyopathy Treatment anticoagulant History serious neurologic disease cerebral hemorrhage , stroke transient ischemic attack Diagnosis asthma Clinically significant gastrointestinal impairment could interfere drug absorption Hematocrit &lt; 35 % Hyperlipidemic fasting Total Cholesterol &gt; 220mg/dl Impaired renal function ( Serum creatinine &gt; 1.5 mg/dl ) History presence immunological hematological disorder Any underlying acute disease require regular medication could possible pose threat subject make implementation protocol interpretation study result difficult Impaired hepatic function ( Serum glutamic oxaloacetic transaminase , serum glutamate pyruvate transaminase &gt; 60 ) Treatment chronic systemic glucocorticoid therapy ( 7 day 1 month ) Treatment lithium salt History Alcohol drug abuse Treatment investigational drug 1 month precede study Mental condition render subject unable understand nature , scope possible consequence study Inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Bradykinin</keyword>
	<keyword>Obesity</keyword>
	<keyword>Nitric Oxide Donor</keyword>
	<keyword>tissue type plasminogen activator</keyword>
	<keyword>isosorbide dinitrate</keyword>
	<keyword>phosphodiesterase inhibitor</keyword>
	<keyword>Renin-Angiotensin Aldosterone System</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>Angiotensin convert enzyme</keyword>
</DOC>